{"id":"W3008873783","doi":"10.1200/jco.2020.38.6_suppl.119","title":"TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Docetaxel; Oncology; Taxane; Phases of clinical research; Interim analysis; Febrile neutropenia; Urology; Cancer; Chemotherapy; Neutropenia; Clinical trial; Breast cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002305159,0.001647061,0.001426079,0.0005992505,0.0004667046,0.001119842,0.001060041,0.00126022,0.005945148],"category_scores_gemma":[0.001032486,0.0005826137,0.001343135,0.0003613809,0.0007491326,0.0008270753,0.0004968927,0.002812017,0.001268972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008434902,"about_ca_system_score_gemma":0.001891686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001143875,"about_ca_topic_score_gemma":0.003564844,"domain_scores_codex":[0.9996042,0.0001700191,0.00001740228,0.0000638849,0.00004445422,0.0001001483],"domain_scores_gemma":[0.9992363,0.00009644705,0.0001134688,0.00004295505,0.000050351,0.0004603637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6973263,0.09637129,0.01262116,0.001437113,0.002628784,0.0006210348,0.0005338675,0.004666564,0.04880973,0.0007181054,0.01519419,0.119072],"study_design_scores_gemma":[0.6687053,0.3078333,0.01091287,0.00005741479,0.0007801414,0.0005164684,0.00009088789,0.001697793,0.003945549,0.0004445271,0.004973537,0.00004216297],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739336,0.003064862,0.00123275,0.001265933,0.0002174766,0.009045723,0.005593216,0.0002627782,0.005383629],"genre_scores_gemma":[0.9718053,0.002191256,0.002919597,0.002294678,0.0002145753,0.005717679,0.009040757,0.00007093333,0.005745104],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005945148,"threshold_uncertainty_score":0.01988852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1525029569294908,"score_gpt":0.5082804380046673,"score_spread":0.3557774810751765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}